RCS - Nuformix PLC - Investor Online Q&A

NuformixAnnouncement

02/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230602:nRSB4197Ba&default-theme=true

RNS Number : 4197B  Nuformix PLC  02 June 2023

REACH

 

2 June 2023

 

Nuformix plc

 

("Nuformix" or the "Company" or the "Group")

 

Investor Online Q&A

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, is pleased to
announce that the Company's Executive Director, Dr Dan Gooding, will be
hosting an online Q&A session at 5.30 p.m. GMT on Tuesday 13 June 2023.
This session is open to all existing and prospective shareholders.  Those who
wish to attend should register via the following link where they will be
provided with access details:

 

https://us02web.zoom.us/webinar/register/WN_fV_2UztcQLSl1S1tC4vTGg
(https://us02web.zoom.us/webinar/register/WN_fV_2UztcQLSl1S1tC4vTGg)

 

Participants will have the opportunity to submit questions during the session,
but questions are welcomed in advance and may be submitted to:
nuformix@investor-focus.co.uk

 

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director                Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes / Bob Pountney (Corporate Broking)     +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of pre-clinical assets with potential
for significant value and early licensing opportunities.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUAUWROBUNRAR